Clinical Trials Logo

Acne Vulgaris clinical trials

View clinical trials related to Acne Vulgaris.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06451237 Completed - Acne Vulgaris Clinical Trials

Acne Remission Maintenance by Weekend Systemic Isotretinoin

Start date: January 20, 2018
Phase: Phase 3
Study type: Interventional

The goal of this study is to learn if isotretinoin oral tablets as a weekend regimen are safe and effective to maintain freedom from acne lesions in young adults who have completed a full course of isotretinoin on daily basis and achieved total control of the acne activity.

NCT ID: NCT06420804 Completed - Clinical trials for Mild to Moderate Acne

Evaluation of the Safety and Efficacy of an Acne Treatment Device

Start date: October 15, 2020
Phase: N/A
Study type: Interventional

A 50-patient study in which 400 microamps of direct current was applied 3 days per week. All tolerability, safety and efficacy endpoints were met.

NCT ID: NCT06415292 Completed - Acne Vulgaris Clinical Trials

A Study to Evaluate the Impact of Clacoterone 1% Cream on Skin Barrier Properties in Acne Prone Patients

Start date: November 27, 2023
Phase: Phase 4
Study type: Interventional

Acne medications are a common source of facial dryness resulting in skin barrier damage and poor patient compliance. Retinoids and benzoyl peroxide are some of the most frequently prescribed and effective acne medications, however, dryness is an unwanted side effect. A new acne medication, 1% clascoterone, has been placed in a novel vehicle for excellent drug delivery in combination with excellent barrier properties. The barrier properties of 1% clascoterone have never been demonstrated. This study is aimed at better understanding the positive barrier effects of 1% clascoterone.

NCT ID: NCT06179056 Completed - Acne Vulgaris Clinical Trials

Anti-microbial Role of Non-antibiotic Agents Against Cutibacterium Acnes in Patients With Acne Vulgaris

Start date: March 1, 2023
Phase:
Study type: Observational

- To evaluate and compare the anti-biofilm activity of Salicylic acid, Isotretinoin, and N-acetylcysteine against C. acne . - To assess the possible role of Salicylic acid, Isotretinoin, and N-acetylcysteine in improving the susceptibility of C. acne for Azithromycin and Doxycycline.

NCT ID: NCT06170593 Completed - Acne Vulgaris Clinical Trials

Intralesional Injections of Triamcinolone for Acne Vulgaris

ATM-2201
Start date: November 15, 2022
Phase: N/A
Study type: Interventional

This proof-of-concept study seeks to investigate the safety of intralesional injections of triamcinolone for acne vulgaris lesions using an Intradermal Needle Adapter.

NCT ID: NCT06149065 Completed - Acne Clinical Trials

Factors Associated With the Acne Severity Among Transmen Population: a Cross-sectional Study

Start date: June 5, 2021
Phase:
Study type: Observational [Patient Registry]

The goal of this observational cross-sectional study is to identify factors associated with severity of acne in Thai transmen receiving masculinizing hormone therapy. The main questions it aims to answer are: - What are the factors associated with severity of acne in transmen? - Does masculinizing hormone therapy associate with the severity of acne in transmen? Participants will be asked to complete an online questionnaire and allow to take pictures of their face for acne assessment purpose.

NCT ID: NCT06122467 Completed - Acne Clinical Trials

A Single Group Study to Evaluate the Efficacy of a Cosmetic Product Line on Acne Symptoms

Start date: October 2, 2023
Phase: N/A
Study type: Interventional

This twelve-week trial will examine the effectiveness of a Menning Labs EQ Product Line acne product. Participants will use the exfoliating cleanser, cream, and gel daily for 8 weeks. Participants will complete questionnaires at Baseline, Day 1, Day 3, Day 7, Day 28, Day 42, and Day 56. Participants will also provide before-and-after photos at Baseline, Day 7, and Day 42, as well as undergo expert skin grading at Baseline and Day 42. The questionnaire on Day 56 will mark the conclusion of the trial.

NCT ID: NCT06063473 Completed - Acne Vulgaris Clinical Trials

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris

Start date: February 22, 2023
Phase: Phase 1
Study type: Interventional

To demonstrate therapeutic equivalence and safety of Trifarotene cream 0.005% (Taro Pharmaceuticals U.S.A., Inc.) and AKLIEF® cream in the treatment of acne vulgaris

NCT ID: NCT06004583 Completed - Acne Vulgaris Clinical Trials

C-Reactive Protein/Albumin Ratio and Acne Vulgaris

Start date: January 5, 2022
Phase:
Study type: Observational

Objective: Acne vulgaris, an inflammatory disease, was investigated in this study with the claim that C-reactive protein (CRP) / albumin ratio and some hematological parameter ratios have the potential to be used as inflammatory markers to monitor disease severity and prognosis. Methods: A descriptive cross-sectional study was conducted with two groups of patients aged 18-65 years, 61 patients diagnosed with acne vulgaris and 35 healthy control patients, and routine hemogram and biochemical parameters were compared. The Global Acne Severity Index was used to determine the severity of acne vulgaris.

NCT ID: NCT05982613 Completed - Acne Vulgaris Clinical Trials

Effectiveness of Standard Therapy of Acne Vulgaris

Start date: April 18, 2023
Phase:
Study type: Observational

This study was to evaluate the effectiveness of standard therapy for acne vulgaris (AV) based on the clinical practice guidelines (CPG) in Indonesia. The main questions it aims to answer were: 1. How is the clinical characteristics of patients with AV in dr.Cipto Mangunkusumo Hospital? 2. How is the effectiveness of standard therapy for AV based on the CPG in Indonesia in reducing the number of non-inflammatory, inflammatory, and total lesions and degree of acne severity? The clinical pratice guideline (CPG) used for analysis was CPG by dr.Cipto Mangunkusumo Hospital 2017 in line with the date of patient visit. Data of 724 patients with AV in dr.Cipto Mangunkusumo Hospital as recorded in the medical records were assessed for eligibility. Data of 3-month-follow-up data of included subjects were collected and analyzed.